CN115154465A - 化合物治疗犬中退行性关节疾病的疼痛和炎症的用途 - Google Patents
化合物治疗犬中退行性关节疾病的疼痛和炎症的用途 Download PDFInfo
- Publication number
- CN115154465A CN115154465A CN202210698831.5A CN202210698831A CN115154465A CN 115154465 A CN115154465 A CN 115154465A CN 202210698831 A CN202210698831 A CN 202210698831A CN 115154465 A CN115154465 A CN 115154465A
- Authority
- CN
- China
- Prior art keywords
- treatment
- dose
- administered
- pain
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 74
- 208000002193 Pain Diseases 0.000 title claims abstract description 71
- 230000036407 pain Effects 0.000 title claims abstract description 62
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 42
- 150000001875 compounds Chemical class 0.000 title claims abstract description 38
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 34
- 241000282472 Canis lupus familiaris Species 0.000 title claims description 56
- 238000011282 treatment Methods 0.000 claims abstract description 116
- 230000037396 body weight Effects 0.000 claims abstract description 84
- 239000003814 drug Substances 0.000 claims abstract description 39
- 210000004369 blood Anatomy 0.000 claims abstract description 10
- 239000008280 blood Substances 0.000 claims abstract description 10
- 208000030175 lameness Diseases 0.000 claims description 42
- 206010003246 arthritis Diseases 0.000 claims description 23
- 230000001225 therapeutic effect Effects 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 9
- 208000000094 Chronic Pain Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000037976 chronic inflammation Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 6
- 238000002559 palpation Methods 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000002459 sustained effect Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000008185 minitablet Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000003442 weekly effect Effects 0.000 description 54
- 238000012423 maintenance Methods 0.000 description 37
- 238000000034 method Methods 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 24
- 230000006698 induction Effects 0.000 description 24
- 241000124008 Mammalia Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000000977 initiatory effect Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000011269 treatment regimen Methods 0.000 description 9
- 230000001760 anti-analgesic effect Effects 0.000 description 8
- 210000003127 knee Anatomy 0.000 description 8
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 7
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 7
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 7
- 230000003412 degenerative effect Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 241000282465 Canis Species 0.000 description 4
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 4
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 4
- 208000026816 acute arthritis Diseases 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940111134 coxibs Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- -1 fatty acid esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 2
- 229960004134 propofol Drugs 0.000 description 2
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000005065 subchondral bone plate Anatomy 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001658044 Beata Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382396.1 | 2014-10-16 | ||
| EP14382396.1A EP3009137A1 (en) | 2014-10-16 | 2014-10-16 | Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals |
| PCT/EP2015/073635 WO2016059028A1 (en) | 2014-10-16 | 2015-10-13 | Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals |
| CN201580068592.3A CN107257684A (zh) | 2014-10-16 | 2015-10-13 | 吡唑啉衍生的化合物及其以每周用量方案针对源自哺乳动物中的退行性关节疾病的炎症和疼痛的用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580068592.3A Division CN107257684A (zh) | 2014-10-16 | 2015-10-13 | 吡唑啉衍生的化合物及其以每周用量方案针对源自哺乳动物中的退行性关节疾病的炎症和疼痛的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115154465A true CN115154465A (zh) | 2022-10-11 |
Family
ID=51844648
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210698831.5A Pending CN115154465A (zh) | 2014-10-16 | 2015-10-13 | 化合物治疗犬中退行性关节疾病的疼痛和炎症的用途 |
| CN201580068592.3A Pending CN107257684A (zh) | 2014-10-16 | 2015-10-13 | 吡唑啉衍生的化合物及其以每周用量方案针对源自哺乳动物中的退行性关节疾病的炎症和疼痛的用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580068592.3A Pending CN107257684A (zh) | 2014-10-16 | 2015-10-13 | 吡唑啉衍生的化合物及其以每周用量方案针对源自哺乳动物中的退行性关节疾病的炎症和疼痛的用途 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11154536B2 (enExample) |
| EP (2) | EP3009137A1 (enExample) |
| JP (1) | JP6655625B2 (enExample) |
| CN (2) | CN115154465A (enExample) |
| AR (1) | AR102295A1 (enExample) |
| CA (1) | CA2964428C (enExample) |
| CY (1) | CY1123243T1 (enExample) |
| DK (1) | DK3206684T3 (enExample) |
| ES (1) | ES2828435T3 (enExample) |
| HR (1) | HRP20201233T1 (enExample) |
| HU (1) | HUE050511T2 (enExample) |
| LT (1) | LT3206684T (enExample) |
| MX (1) | MX376725B (enExample) |
| PL (1) | PL3206684T3 (enExample) |
| PT (1) | PT3206684T (enExample) |
| RS (1) | RS60777B1 (enExample) |
| SI (1) | SI3206684T1 (enExample) |
| SM (1) | SMT202000415T1 (enExample) |
| TW (1) | TWI707678B (enExample) |
| WO (1) | WO2016059028A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109303784B (zh) * | 2018-09-30 | 2020-06-23 | 山东省文登整骨医院 | 痛风性关节炎动物模型的构建方法 |
| KR20220007086A (ko) * | 2019-05-08 | 2022-01-18 | 노파르티스 아게 | T1dm 및 췌도염의 치료에 사용하기 위한 항-cd40 항체 |
| EP4029502A1 (en) | 2021-01-15 | 2022-07-20 | Ecuphar N.V. | Pyrazoline-derived compound (enflicoxib) for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals |
| US12208085B2 (en) | 2022-05-31 | 2025-01-28 | Ecuphar Nv | Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1307566A (zh) * | 1998-05-29 | 2001-08-08 | 埃斯蒂文博士实验室股份有限公司 | 吡唑啉衍生物、它们的制备方法和作为药物的应用 |
| AU3823202A (en) * | 1997-05-05 | 2002-06-20 | Pfizer Inc. | Cox-2 selective carprofen for treating pain and inflammation in dogs |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050131028A1 (en) * | 2003-09-11 | 2005-06-16 | Pharmacia Corporation | Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders |
| RU2007137489A (ru) * | 2005-03-10 | 2009-04-20 | Дженентек, Инк. (Us) | Способы и композиции для модуляции целостности сосудов |
-
2014
- 2014-10-16 EP EP14382396.1A patent/EP3009137A1/en not_active Withdrawn
-
2015
- 2015-10-13 PL PL15778958T patent/PL3206684T3/pl unknown
- 2015-10-13 RS RS20200943A patent/RS60777B1/sr unknown
- 2015-10-13 PT PT157789587T patent/PT3206684T/pt unknown
- 2015-10-13 HU HUE15778958A patent/HUE050511T2/hu unknown
- 2015-10-13 US US15/518,871 patent/US11154536B2/en active Active
- 2015-10-13 ES ES15778958T patent/ES2828435T3/es active Active
- 2015-10-13 SI SI201531302T patent/SI3206684T1/sl unknown
- 2015-10-13 WO PCT/EP2015/073635 patent/WO2016059028A1/en not_active Ceased
- 2015-10-13 HR HRP20201233TT patent/HRP20201233T1/hr unknown
- 2015-10-13 CN CN202210698831.5A patent/CN115154465A/zh active Pending
- 2015-10-13 CA CA2964428A patent/CA2964428C/en active Active
- 2015-10-13 DK DK15778958.7T patent/DK3206684T3/da active
- 2015-10-13 JP JP2017539508A patent/JP6655625B2/ja active Active
- 2015-10-13 CN CN201580068592.3A patent/CN107257684A/zh active Pending
- 2015-10-13 LT LTEP15778958.7T patent/LT3206684T/lt unknown
- 2015-10-13 EP EP15778958.7A patent/EP3206684B1/en active Active
- 2015-10-13 MX MX2017004899A patent/MX376725B/es active IP Right Grant
- 2015-10-13 SM SM20200415T patent/SMT202000415T1/it unknown
- 2015-10-16 TW TW104134072A patent/TWI707678B/zh active
- 2015-10-16 AR ARP150103353A patent/AR102295A1/es not_active Application Discontinuation
-
2020
- 2020-08-03 CY CY20201100714T patent/CY1123243T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3823202A (en) * | 1997-05-05 | 2002-06-20 | Pfizer Inc. | Cox-2 selective carprofen for treating pain and inflammation in dogs |
| CN1307566A (zh) * | 1998-05-29 | 2001-08-08 | 埃斯蒂文博士实验室股份有限公司 | 吡唑啉衍生物、它们的制备方法和作为药物的应用 |
Non-Patent Citations (2)
| Title |
|---|
| RAQUEL F. REINOSO等: "pharmacokinetics of E-6087, a New Anti-infIammatory Agent, in Rats and Dogs", BIOPHARMACEUTICS & DRUG DISPOSITION, vol. 22, no. 6, pages 231 - 242, XP002736707, DOI: 10.1002/bdd.258 * |
| S.R.COX等: "the pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs", JOURANL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, vol. 33, no. 5, pages 461 - 470, XP002736708, DOI: 10.1111/j.1365-2885.2010.01165.x * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017531042A (ja) | 2017-10-19 |
| HUE050511T2 (hu) | 2020-12-28 |
| LT3206684T (lt) | 2020-10-12 |
| CA2964428C (en) | 2022-01-04 |
| US11154536B2 (en) | 2021-10-26 |
| EP3206684B1 (en) | 2020-06-17 |
| EP3009137A1 (en) | 2016-04-20 |
| EP3206684A1 (en) | 2017-08-23 |
| RS60777B1 (sr) | 2020-10-30 |
| TW201625239A (zh) | 2016-07-16 |
| MX376725B (es) | 2025-03-07 |
| AR102295A1 (es) | 2017-02-15 |
| SI3206684T1 (sl) | 2020-11-30 |
| TWI707678B (zh) | 2020-10-21 |
| DK3206684T3 (da) | 2020-08-10 |
| CY1123243T1 (el) | 2021-10-29 |
| US20170231961A1 (en) | 2017-08-17 |
| WO2016059028A1 (en) | 2016-04-21 |
| PT3206684T (pt) | 2020-08-24 |
| SMT202000415T1 (it) | 2020-11-10 |
| ES2828435T3 (es) | 2021-05-26 |
| JP6655625B2 (ja) | 2020-02-26 |
| MX2017004899A (es) | 2018-02-12 |
| PL3206684T3 (pl) | 2021-01-11 |
| CA2964428A1 (en) | 2016-04-21 |
| HRP20201233T1 (hr) | 2020-11-13 |
| CN107257684A (zh) | 2017-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6676062B2 (ja) | 認知低下を処置するための方法 | |
| JP2007302657A (ja) | 痙症の兆候および症候の緩和方法 | |
| TW202042802A (zh) | 藉由投與樹脂毒素(resiniferatoxin)治療骨關節炎疼痛之方法 | |
| AU2006232644B2 (en) | Anti-inflammatory formulation | |
| CN115154465A (zh) | 化合物治疗犬中退行性关节疾病的疼痛和炎症的用途 | |
| TW202237107A (zh) | 用於治療疼痛之酚系trpv1促效劑之前藥 | |
| EP2413970B1 (en) | New therapeutic approaches for treating neuroinflammatory conditions | |
| ES2973249T3 (es) | Composición que comprende cepa de Agathobaculum sp. como ingrediente efectivo para la prevención, alivio o tratamiento del trastorno del espectro autista | |
| EP1834647A1 (en) | Canine and equine collagen joint health supplement | |
| WO2015084706A1 (en) | Intra-articular formulations and methods for treatment of osteoarthritis | |
| US20250161362A1 (en) | Combined preparation for its use in the improvement of the muscle health | |
| KR102320841B1 (ko) | 니클로사마이드를 포함하는 관절염 예방 및 치료용 조성물 | |
| ES3034261T3 (en) | Amiselimod for use in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome | |
| US11364218B2 (en) | Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome | |
| McKune | Clinical Management and Pharmacologic Treatment of Pain | |
| WO2023145735A1 (ja) | サルコペニアを含む老化関連異常の抑制の新規治療と予防 | |
| Pucheu et al. | Multicentric, randomized and positive-controlled study to assess the efficacy of an association of chondroitin sulphate, chitosan, l-selenomethionine and epigallocatechin-3-gallate in the control of osteoarthritis and functional postoperative recovery | |
| CN109789110A (zh) | 包含羟基酪醇和乳香酸的组合物 | |
| US20100203146A1 (en) | Intermittent dosing strategy for treating rheumatoid arthritis | |
| JP2017507941A (ja) | 機械的な神経損傷を処置するための新規組成物 | |
| Wijayanti et al. | The comparison of doxycycline residue in the meat of broiler chickens administered in feed and water | |
| AU2020263152A1 (en) | Compositions and methods for potentiating derivatives of 4-Aminophenols | |
| Hardeman | The potential role of Clostridium botulinum toxin in the treatment of equine laminitis | |
| Laniesse | Pharmacology and antinociception of a sustained-released butorphanol-poloxamer 407 formulation in Amazon parrots | |
| LASCELLES | Supportive Care for |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |